Should You Take Anastrozole With Testosterone On TRT?

Most men on testosterone replacement therapy don't need anastrozole. In the largest real-world study on this question, researchers at Memorial Sloan Kettering reviewed 1,708 men receiving testosterone therapy and found that only 3% received aromatase inhibitor treatment for elevated estradiol (Punjani et al., 2021). The Endocrine Society's 2018 clinical practice guideline does not recommend routine aromatase inhibitor use alongside TRT (Bhasin et al., 2018).

Anastrozole is an aromatase inhibitor that inhibits the enzyme responsible for converting testosterone into estradiol, the primary form of estrogen in men. It is FDA-approved for breast cancer treatment in postmenopausal women but used off-label when men on TRT develop confirmed high estradiol with symptoms such as breast tissue growth, fluid retention, or mood changes.

That off-label distinction matters. No professional medical society endorses adding anastrozole as a default part of a TRT protocol. When it is prescribed, the decision is generally guided by lab-confirmed elevated estradiol combined with symptoms, not by a blanket approach.

What Does Anastrozole Do on TRT?

Anastrozole inhibits the aromatase enzyme, which converts testosterone into estradiol.

When a man begins TRT, his circulating testosterone levels rise. More testosterone creates more substrate for aromatase, an enzyme concentrated in adipose tissue, bone, and the brain. Some men on TRT see their estradiol climb alongside testosterone as a result. Anastrozole reduces that conversion without lowering the testosterone dose itself.

Estradiol isn't a waste product. A study published in the New England Journal of Medicine found that among men with testosterone levels of 200 to 400 ng/dL, those with estradiol below 10 pg/mL experienced a 31% decline in sexual desire scores. Men with estradiol at or above 10 pg/mL saw only a 13% decline (Finkelstein et al., 2013). Estradiol also plays a role in bone mineral density, cardiovascular function, and cognitive health in men (Schulster et al., 2016). The goal of anastrozole is not to eliminate estradiol but to prevent levels from rising high enough to cause problems while preserving its protective effects.

When Providers Add Anastrozole to TRT

The prevailing clinical approach is symptom-driven rather than preventative, though practice varies.

A survey of 489 International Society of Sexual Medicine (ISSM) members found that roughly 69% of clinicians prescribe an aromatase inhibitor to men showing symptoms of elevated estrogen on TRT. About 48% prescribe it when lab values are high but the patient is asymptomatic. Only 14% add it prophylactically at the start of therapy (Butaney et al., 2020). Anastrozole was the most commonly prescribed medication, used by 62% of respondents.

Symptoms that prompt consideration include gynecomastia (breast tissue development), fluid retention, mood instability, and sexual dysfunction. Most providers recommend lab confirmation before adding an aromatase inhibitor. Estradiol levels above 40-60 pg/mL, measured by a sensitive E2 assay (not a standard immunoassay, which lacks accuracy at lower male-range concentrations), represent a commonly used threshold.

Before adding a second medication, the first-line approach is often adjusting the testosterone protocol. Lowering the dose, increasing injection frequency (switching from weekly to twice-weekly, for instance), or addressing body composition can all reduce aromatization. Adipose tissue is where aromatase concentrates, so men carrying more body fat tend to convert more testosterone to estradiol.

Dosing and Lab Thresholds

Providers commonly start at 0.25 mg to 0.5 mg, taken two to three times per week on injection days or the day after.

In the Punjani et al. (2021) study, men with estradiol above 60 pg/mL (or 40-60 pg/mL with symptoms) were started at 0.5 mg three times per week. Median estradiol dropped from 65 pg/mL to 22 pg/mL (P < .001), and total testosterone levels remained stable at 596 ng/dL compared to 616 ng/dL before treatment (Punjani et al., 2021). Most providers target an estradiol range of 20-40 pg/mL.

Most providers recheck labs every 2-3 months during initial adjustment, then every 6-12 months once levels stabilize. Anastrozole prescribed without scheduled follow-up lab work risks over-suppression, which carries its own set of complications.

Do All Men on TRT Need an Aromatase Inhibitor?

No. The most cited clinical guidelines don't endorse routine use.

The Endocrine Society's 2018 guideline recommends monitoring testosterone, hematocrit, and symptoms during TRT but makes no recommendation for routine aromatase inhibitor co-prescription (Bhasin et al., 2018). The American Urological Association (AUA) guideline acknowledges aromatase inhibitors as an option for men with testosterone deficiency who want to preserve fertility, but does not position them as standard TRT adjuncts (Mulhall et al., 2018).

The clinical debate centers on whether elevated estradiol on TRT should be managed by adjusting the testosterone dose or by adding a second drug. Providers who favor dose adjustment argue that estradiol's protective benefits shouldn't be suppressed unless the patient is clearly symptomatic. Others counter that lowering the testosterone dose may bring back the symptoms that TRT was prescribed to address.

This is where individualized care matters more than fixed protocols. The decision to add or withhold an aromatase inhibitor should involve a conversation between the patient and their prescribing provider, weighing symptoms, lab findings, and the patient's treatment goals. Providers who manage TRT with regular lab monitoring and sensitive estradiol testing can titrate the balance between testosterone, estradiol, and symptom control without over-correcting in either direction.

Anastrozole Without Testosterone

Some men are prescribed anastrozole on its own, most often when fertility preservation is a priority.

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing LH and FSH secretion and can significantly suppress sperm production. For men with secondary hypogonadism who want to raise testosterone while maintaining fertility, anastrozole inhibits aromatization of endogenous testosterone, reduces estradiol's negative feedback on the hypothalamus, and allows LH to rise. This can stimulate testicular testosterone production without suppressing spermatogenesis.

The AUA guideline recognizes aromatase inhibitors as one option for testosterone-deficient men who want to maintain fertility (Mulhall et al., 2018). This use, like its application alongside TRT, remains off-label.

Risks of Over-Suppressing Estradiol

Providers report that common short-term side effects of anastrozole (hot flashes, joint discomfort, musculoskeletal pain, headaches, dizziness, among other possible effects) tend to be manageable and may resolve within a few months. The serious risks come from driving estradiol too low.

Bone density loss is the most studied long-term concern. The ATAC trial, which followed patients taking anastrozole for breast cancer over five years, found accelerated bone mineral density loss during the treatment period (Eastell et al., 2008). While that data comes from a female population, the underlying mechanism (estradiol suppression impairing bone turnover) is understood to be relevant in men as well, though long-term data specific to male populations on short-term AI use remain limited.

In men, estradiol below 10-20 pg/mL has been associated with increased body fat, reduced lean mass, and sexual dysfunction (Finkelstein et al., 2013). Prolonged suppression below this range may compromise skeletal health and raise fracture risk over time.

This is the core argument against unsupervised anastrozole use. The drug works, but it works too aggressively if dosing isn't guided by lab data. Self-medicating or sourcing anastrozole outside a clinical setting bypasses the evaluation, testing, and follow-up that separate responsible estrogen management from unmonitored hormone management.

Does Anastrozole Help With Erectile Dysfunction?

Some evidence connects elevated estradiol to erectile dysfunction. A 2020 study in the Asian Journal of Andrology found an independent association between elevated estradiol and ED risk in men (Li et al., 2020).

Correlation isn't causation, though. No large trial supports anastrozole as a first-line ED treatment. When men on TRT report improvement in erectile function after starting anastrozole, the likely explanation is that their estradiol was in fact elevated and contributing to the problem. Anastrozole didn't treat the ED directly. It may have addressed a hormonal factor that contributed to the dysfunction.

Men dealing with erectile dysfunction may benefit from providers who evaluate the full hormonal picture, including testosterone, estradiol, prolactin, and thyroid markers, rather than attributing the problem to a single variable.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Is anastrozole FDA-approved for men on TRT?

No. Anastrozole is FDA-approved for breast cancer treatment in postmenopausal women. Its use in men on testosterone therapy is off-label. Off-label prescribing is legal and common in medicine when ordered by a licensed provider, but it means no large-scale trial has evaluated anastrozole specifically for this purpose in men.

What estradiol level is too high on TRT?

Most providers consider estradiol above 40-60 pg/mL as the threshold for intervention, especially when measured by a sensitive E2 assay. In the Punjani et al. (2021) study of 1,708 men, those started on anastrozole had a median pre-treatment estradiol of 65 pg/mL. Levels below 20 pg/mL generally indicate over-suppression.

How long does it take for anastrozole to lower estradiol?

Anastrozole has a half-life of approximately 50 hours. Most patients see measurable estradiol reductions within 1-2 weeks of starting, with full effects visible on lab work after 4-6 weeks. Providers typically recheck levels at 8-12 weeks to adjust dosing.

Can anastrozole cause bone loss in men?

Prolonged estradiol suppression below 10-20 pg/mL is associated with reduced bone mineral density in both men and women. The ATAC trial found accelerated bone loss over five years of anastrozole treatment. This risk is why lab monitoring is required, as short-term, dose-adjusted use with estradiol kept in the 20-40 pg/mL range is less likely to affect bone health.

What are the alternatives to anastrozole on TRT?

Lowering the testosterone dose, increasing injection frequency (such as switching from weekly to twice-weekly), and reducing body fat can all lower estradiol without adding a second medication. These adjustments reduce peak testosterone levels and the aromatase activity that drives estradiol conversion.

Does anastrozole affect fertility?

Anastrozole does not directly suppress fertility the way exogenous testosterone does. When used without testosterone, it may actually support fertility by raising endogenous testosterone through reduced estradiol feedback, which preserves LH and FSH levels. The AUA guideline acknowledges this use as one option for testosterone-deficient men who want to maintain sperm production.

References

• Bhasin S, et al. J Clin Endocrinol Metab. 2018;103(5):1715–1744

• Butaney M, et al. Urology. 2020;139:104–109

• Eastell R, et al. J Clin Oncol. 2008;26(7):1051–1057

• Finkelstein JS, et al. N Engl J Med. 2013;369(11):1011–1022

• Li JY, et al. Asian J Androl. 2020;22(6):587–592

• Mulhall JP, et al. J Urol. 2018;200(2):423–432

• Punjani N, et al. Sex Med. 2021;9(4):100378

• Schulster M, et al. Asian J Androl. 2016;18(3):435–440